CURI vs LOB

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 02, 2026

CURI

38.3
AI Score
VS
CURI Wins

LOB

37.7
AI Score

Investment Advisor Scores

CURI

38score
Recommendation
AVOID NEW MONEY

LOB

38score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric CURI LOB Winner
Forward P/E 9.2937 10.1937 CURI
PEG Ratio 0 0 Tie
Revenue Growth 22.3% 12.2% CURI
Earnings Growth 1400.0% 45.1% CURI
Tradestie Score 38.3/100 37.7/100 CURI
Profit Margin 0.0% 26.5% LOB
Beta 1.00 1.00 Tie
AI Recommendation AVOID NEW MONEY AVOID NEW MONEY Tie

Relative Price Performance (Last 90 Days)

CURI 1M: -0.3% · 3M: +3.4% LOB 1M: -7.2% · 3M: -12.2%

Current Technical Phase

CURI

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (2.8% over 20 days), RSI 53

RSI (14): 52.8 · Price: $2.91

LOB

Markdown
Sell / avoid

Price below a falling SMA50 (slope -3.4%), weak momentum, RSI 31

RSI (14): 31.4 · Price: $36.68

Fundamentals Snapshot

Metric CURI LOB
Market Cap — —
Forward P/E 9.4 8.7
Trailing P/E — 12.7
Revenue (TTM) — —
Revenue Growth 0.2% 0.1%
Gross Margin 0.6% 1.0%
Operating Margin 0.4% 0.4%
EPS -0.01 2.86
Dividend Yield 0.11% 0.00%

Frequently Asked Questions

Based on our detailed analysis, CURI is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.